Maker of the t:slim X2 insulin pump with Control-IQ automated dosing technology for people with diabetes.
Maker of the t:slim X2 insulin pump with Control-IQ automated dosing technology for people with diabetes.
Earns on the pump once, then repeatedly on disposable cartridges and infusion sets that users replace every few days, so installed users matter more than new pump sales. A growing share of orders goes through pharmacies rather than medical-equipment suppliers, and the pump connects with sensors from Dexcom and Abbott.
Moat: narrow (IP / patents, switching costs, brand). Established Control-IQ algorithm and CGM integrations create switching costs once patients are on therapy.
Headquarters: San Diego, California · Founded: 2006 · Employees: 2,500
Size Tandem Diabetes Care (TNDM) is a United States Health Care company (Medical Specialties) with a market value of $1.19B, the 2126th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.05 on 18 Nov 2026.
Performance Over six months the shares gained 13.4%, against -14.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 6.7% over the last twelve months (peer median +13.5%); the operating margin is -2.5% (peer median 16.0%).
Valuation It trades at 1.4× enterprise value to sales against a peer median of 4.7× (cheapest of 20).
Capital Return on invested capital runs 15.1 points below its cost of capital (10.2% WACC).
Credit Tandem Diabetes Care has 2 bonds outstanding ($616M).
Short interest Short interest is 23.2% of the free float (30 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.07B | $1.02B | $940M | $748M | $801M |
| Revenue growth | — | +8% | +26% | -7% | — |
| Gross profit | $608M | $531M | $475M | $354M | $401M |
| EBITDA | -$8.40M | -$59.8M | -$82.5M | -$139M | -$47.5M |
| Net income | -$49.2M | -$205M | -$96.0M | -$223M | -$94.6M |
| Free cash flow | -$36.3M | -$29.7M | $4.99M | -$58.6M | $16.4M |
| Capital expenditure | $21.7M | $19.9M | $19.2M | $26.8M | $34.1M |
| Total debt | $737M | $449M | $474M | $416M | $420M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tandem Diabetes Care TNDM | $1.19B | +13% | +7% | -2% | 1.4× | n/a |
| Insulet PODD | $9.71B | -11% | +26% | 18% | 3.2× | 10.6% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 4.0× | 9.1% |
| Beta Bionics BBNX | $779M | +42% | +44% | -73% | 4.3× | n/a |
| Dexcom DXCM | $30.8B | +16% | +13% | 24% | 6.0× | 19.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TNDM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.2% | -7.5% | 7th highest of 21 |
| 6-month return | +13.4% | -14.3% | 3rd highest of 20 |
| Distance from 52-week high | -42.5% | -37.5% | 8th lowest of 21 |
| Revenue growth (TTM) | +6.7% | +13.5% | 7th lowest of 19 |
| Operating margin | -2.5% | 16.0% | 5th lowest of 20 |
| EV / Sales | 1.4× | 4.7× | cheapest of 20 |
| ROIC minus cost of capital | -15.1 pp | +0.2 pp | 4th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | 1.4× | n/a | n/a |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | 2% | 10.6× | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.21B | -16% | +21% | 16% | 5.0× | 10.3% | +40.3% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 4.7× | 11.3% | -3.5% |
| Sansure Biotech 688289.SS | China | $1.24B | -17% | -1% | 1% | 3.8× | n/a | n/a |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 5.8× | 1.7% | +9.9% |
| NovoCure NVCR | United States | $1.25B | -40% | +13% | -17% | 1.4× | n/a | n/a |
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 3.4× | 35.1% | +7.9% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 1.9× | n/a | n/a |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | 4.7× | n/a | n/a |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 3.3× | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 4.0× | -9.2% | +34.5% |
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 15.4× | 22.8% | +23.6% |
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 13.4× | 20.7% | +27.6% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 1.7× | 5.9% | +3.6% |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 6.3× | 8.8% | +8.8% |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 3.8× | 8.3% | +16.5% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | 85.0× | n/a | n/a |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | 4.3× | n/a | n/a |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 11.1× | 18.5% | +21.5% |
Tandem Diabetes Care has 2 bonds outstanding with $616M face value.